vs
Side-by-side financial comparison of Biogen (BIIB) and Eastman Chemical Company (EMN). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.3B vs $2.0B, roughly 1.2× Eastman Chemical Company). Eastman Chemical Company runs the higher net margin — 5.3% vs -2.1%, a 7.5% gap on every dollar of revenue. On growth, Biogen posted the faster year-over-year revenue change (-7.1% vs -13.8%). Over the past eight quarters, Biogen's revenue compounded faster (-0.2% CAGR vs -8.6%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Eastman Chemical Company is an American chemical products manufacturer based in Kingsport, Tennessee. Founded in 1920, it was formerly a subsidiary of Kodak until 1994. The company is an independent global specialty materials company that produces a broad range of advanced materials, chemicals and fibers for everyday purposes. It operates 36 manufacturing sites worldwide and employs approximately 14,000 people. In 2023, Eastman had sales revenue of approximately $9.21 billion.
BIIB vs EMN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $2.0B |
| Net Profit | $-48.9M | $105.0M |
| Gross Margin | 78.3% | 17.1% |
| Operating Margin | -2.5% | — |
| Net Margin | -2.1% | 5.3% |
| Revenue YoY | -7.1% | -13.8% |
| Net Profit YoY | -118.3% | -42.3% |
| EPS (diluted) | $-0.35 | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.0B | ||
| Q4 25 | $2.3B | $2.0B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.6B | $2.3B | ||
| Q1 25 | $2.4B | $2.3B | ||
| Q4 24 | $2.5B | $2.2B | ||
| Q3 24 | $2.5B | $2.5B | ||
| Q2 24 | $2.5B | $2.4B |
| Q1 26 | — | $105.0M | ||
| Q4 25 | $-48.9M | $105.0M | ||
| Q3 25 | $466.5M | $47.0M | ||
| Q2 25 | $634.8M | $140.0M | ||
| Q1 25 | $240.5M | $182.0M | ||
| Q4 24 | $266.7M | $330.0M | ||
| Q3 24 | $388.5M | $180.0M | ||
| Q2 24 | $583.6M | $230.0M |
| Q1 26 | — | 17.1% | ||
| Q4 25 | 78.3% | 17.1% | ||
| Q3 25 | 73.4% | 19.7% | ||
| Q2 25 | 77.1% | 22.1% | ||
| Q1 25 | 74.1% | 24.8% | ||
| Q4 24 | 76.2% | 24.7% | ||
| Q3 24 | 74.1% | 24.6% | ||
| Q2 24 | 77.8% | 25.3% |
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 0.6% | ||
| Q3 25 | 22.0% | 6.1% | ||
| Q2 25 | 28.1% | 7.4% | ||
| Q1 25 | 12.8% | 11.0% | ||
| Q4 24 | 11.9% | 13.2% | ||
| Q3 24 | 18.3% | 11.4% | ||
| Q2 24 | 28.3% | 12.1% |
| Q1 26 | — | 5.3% | ||
| Q4 25 | -2.1% | 5.3% | ||
| Q3 25 | 18.4% | 2.1% | ||
| Q2 25 | 24.0% | 6.1% | ||
| Q1 25 | 9.9% | 7.9% | ||
| Q4 24 | 10.9% | 14.7% | ||
| Q3 24 | 15.8% | 7.3% | ||
| Q2 24 | 23.7% | 9.7% |
| Q1 26 | — | $0.93 | ||
| Q4 25 | $-0.35 | $0.93 | ||
| Q3 25 | $3.17 | $0.40 | ||
| Q2 25 | $4.33 | $1.20 | ||
| Q1 25 | $1.64 | $1.57 | ||
| Q4 24 | $1.82 | $2.81 | ||
| Q3 24 | $2.66 | $1.53 | ||
| Q2 24 | $4.00 | $1.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $566.0M |
| Total DebtLower is stronger | $6.3B | — |
| Stockholders' EquityBook value | $18.3B | $6.0B |
| Total Assets | $29.4B | $14.9B |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $566.0M | ||
| Q4 25 | — | $566.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $837.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
| Q1 26 | — | $6.0B | ||
| Q4 25 | $18.3B | $6.0B | ||
| Q3 25 | $18.2B | $5.8B | ||
| Q2 25 | $17.6B | $5.8B | ||
| Q1 25 | $17.0B | $5.9B | ||
| Q4 24 | $16.7B | $5.8B | ||
| Q3 24 | $16.4B | $5.7B | ||
| Q2 24 | $15.9B | $5.6B |
| Q1 26 | — | $14.9B | ||
| Q4 25 | $29.4B | $14.9B | ||
| Q3 25 | $29.2B | $15.0B | ||
| Q2 25 | $28.3B | $15.2B | ||
| Q1 25 | $28.0B | $15.0B | ||
| Q4 24 | $28.0B | $15.2B | ||
| Q3 24 | $28.3B | $15.1B | ||
| Q2 24 | $26.8B | $14.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | — |
| Free Cash FlowOCF − Capex | $468.0M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $502.0M | ||
| Q3 25 | $1.3B | $402.0M | ||
| Q2 25 | $160.9M | $233.0M | ||
| Q1 25 | $259.3M | $-167.0M | ||
| Q4 24 | $760.9M | $540.0M | ||
| Q3 24 | $935.6M | $396.0M | ||
| Q2 24 | $625.8M | $367.0M |
| Q1 26 | — | — | ||
| Q4 25 | $468.0M | $390.0M | ||
| Q3 25 | $1.2B | $265.0M | ||
| Q2 25 | $134.3M | $83.0M | ||
| Q1 25 | $222.2M | $-314.0M | ||
| Q4 24 | $721.6M | $361.0M | ||
| Q3 24 | $900.6M | $276.0M | ||
| Q2 24 | $592.3M | $252.0M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 19.8% | ||
| Q3 25 | 48.4% | 12.0% | ||
| Q2 25 | 5.1% | 3.6% | ||
| Q1 25 | 9.1% | -13.7% | ||
| Q4 24 | 29.4% | 16.1% | ||
| Q3 24 | 36.5% | 11.2% | ||
| Q2 24 | 24.0% | 10.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 5.7% | ||
| Q3 25 | 1.8% | 6.2% | ||
| Q2 25 | 1.0% | 6.6% | ||
| Q1 25 | 1.5% | 6.4% | ||
| Q4 24 | 1.6% | 8.0% | ||
| Q3 24 | 1.4% | 4.9% | ||
| Q2 24 | 1.4% | 4.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.78× | ||
| Q3 25 | 2.73× | 8.55× | ||
| Q2 25 | 0.25× | 1.66× | ||
| Q1 25 | 1.08× | -0.92× | ||
| Q4 24 | 2.85× | 1.64× | ||
| Q3 24 | 2.41× | 2.20× | ||
| Q2 24 | 1.07× | 1.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
EMN
Segment breakdown not available.
